ANG-3070 / Elicio Therap - LARVOL DELTA

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1b | N=20 | Not yet recruiting | Sponsor: Angion Biomedica Corp

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire) - "Additionally, Angion has completed multiple preclinical studies demonstrating ANG-3070’s activity in IPF models. These studies include: An in vitro study exploring ANG-3070’s ability to inhibit proliferation of normal human lung fibroblasts, key components of the fibrotic pathway in IPF. ANG-3070 successfully inhibited fibroblast proliferation in the presence of PDGF, an important confirmation of ANG-3070’s ability to inhibit a known component of IPF pathophysiology...An in vitro study exposing ANG-3070 to normal human fibroblasts and human small airway epithelial cells, the latter cells being critical to healthy lung function. The ability of ANG-3070 to effectively inhibit fibroblast activation and collagen secretion while sparing small airway epithelial cells in this model suggests potentially increased clinical benefit via protection of the small airway epithelial cells and the alveolar epithelium from further damage."

Preclinical • Idiopathic Pulmonary Fibrosis

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire) - "Angion Biomedica...today announced U.S. Food and Drug Administration’s (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF....The Phase 1b study is intended to start enrollment and report data in 2022. IPF patients eligible for this Phase 1b study of ANG-3070 include those who have discontinued nintedanib or pirfenidone, refused treatment with nintedanib or pirfenidone, or those who are treatment naïve....The results from this study will assist us in designing and enrolling a Phase 2 trial in IPF, which we expect to initiate in 2023. IPF is a serious and ultimately fatal fibrotic disease where additional treatment options are needed."

Enrollment status • IND • New P2 trial • P1 data • Idiopathic Pulmonary Fibrosis

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results (GlobeNewswire) - "Angion Biomedica...Develop ANG-3070 for treatment of patients with idiopathic pulmonary fibrosis (IPF), with a planned IND filing in IPF by the end of 2022"

IND • Idiopathic Pulmonary Fibrosis

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with primary proteinuric renal disease (clinicaltrialsregister.eu) - P2 | N=100 | Ongoing | Sponsor: Angion Biomedica Corp.

New P2 trial • Nephrology • Renal Disease

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Angion Biomedica Corp | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

SAFETY AND EFFICACY OF ANG-3070 IN PATIENTS WITH PRIMARY PROTEINURIC KIDNEY DISEASE: A PHASE 2 STUDY DESIGN (ISN-WCN 2022) - "This phase 2 study will provide data about the safety and efficacy of different dosing regimens of ANG-3070 in PPKD patients that will inform the design of a phase 3 study. This abstract was submitted to American Society of Nephrology Kidney Week 2022."

Clinical • P2 data • Chronic Kidney Disease • Nephrology • Renal Disease

EFFECTS OF ANG-3070 IN A MOUSE MODEL OF ALPORT SYNDROME (ISN-WCN 2022) - "Treatment with a novel tyrosine kinase inhibitor, ANG-3070, was efficacious in AS mice compared with vehicle. ANG-3070 may represent a novel therapeutic for AS.This abstract was submitted to American Society of Nephrology Kidney Week 2022."

Preclinical • Chronic Kidney Disease • Fibrosis • Genetic Disorders • Immunology • Nephrology • Renal Disease • COL4A5 • Collagen Type IV • TGFB1

EFFECT OF ANG-3070 IN THE UNILATERAL URETERAL OBSTRUCTION MOUSE MODEL OF RENAL FIBROSIS (ISN-WCN 2022) - "Daily oral administration of ANG-3070 100 mg/kg reduced renal damage and renal fibrosis in the UUO mouse model.This abstract was submitted to American Society of Nephrology Kidney Week 2022."

Preclinical • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

EFFECT OF ANG-3070 IN THE PASSIVE HEYMANN NEPHRITIS RAT MODEL OF PRIMARY PROTEINURIC KIDNEY DISEASE (ISN-WCN 2022) - "Twice-daily oral administration of the novel tyrosine kinase inhibitor ANG-3070 at 15mg/kg reduces proteinuria, renal fibrosis, glomerulosclerosis, and PDGFRβ expression levels in a rat model of PHN. These data suggest ANG-3070 may be an effective treatment in PPKDs.This abstract was submitted to American Society of Nephrology Kidney Week 2022."

Preclinical • Chronic Kidney Disease • Fibrosis • Glomerulonephritis • Immunology • Nephrology • Renal Disease • GAPDH • PDGFRB

[VIRTUAL] Safety and Efficacy of ANG-3070 in Patients with Primary Proteinuric Kidney Disease: A Phase 2 Study Design (KIDNEY WEEK 2021) - "An independent data monitoring committee will review safety throughout the study. Conclusion This Phase 2 study will provide data about the safety and efficacy of ANG-3070 in PPKD patients that will inform the design of a Phase 3 study."

Clinical • P2 data • Chronic Kidney Disease • Nephrology • Renal Disease • DDR1 • DDR2

[VIRTUAL] Effects of ANG-3070 in a Mouse Model of Alport Syndrome (KIDNEY WEEK 2021) - "Conclusion Treatment with a novel tyrosine kinase inhibitor, ANG-3070, was efficacious in AS mice compared to Vehicle. ANG-3070 may represent a novel therapeutic for AS."

Preclinical • Chronic Kidney Disease • Fibrosis • Genetic Disorders • Immunology • Nephrology • Renal Disease • Collagen Type IV • TGFB1

[VIRTUAL] Effect of ANG-3070 in the Unilateral Ureteral Obstruction Mouse Model of Renal Fibrosis (KIDNEY WEEK 2021) - "Results Animals treated with ANG-3070 had a statistically significant reduction in histological damage as compared to vehicle (Vehicle, 6.4 vs ANG-3070, 4.3; p-value <0.001) and the histological markers of fibrosis, PSR (% control, vehicle, 1458% vs. ANG-3070, 503%; p-value <0.001), and αSMA (% control, vehicle, 511% vs. ANG-3070, 248%; p-value <0.01) as shown in Figure 1. Conclusion Daily oral administration of 100 mg/kg ANG-3070 reduces renal damage and renal fibrosis in a mouse model of renal fibrosis induced by UUO."

Preclinical • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

[VIRTUAL] Effect of ANG-3070 in the Passive Heymann Nephritis Rat Model of Primary Proteinuric Kidney Disease (KIDNEY WEEK 2021) - "Conclusion Twice-daily oral administration of the novel tyrosine kinase inhibitor ANG-3070 reduces proteinuria, renal fibrosis, glomerulosclerosis and PDGFRβ expression levels in a rat model of PHN. These data suggest ANG-3070 may be an effective treatment in PPKDs."

Preclinical • Chronic Kidney Disease • Fibrosis • Glomerulonephritis • Immunology • Nephrology • Renal Disease • GAPDH • PDGFRB

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis (GlobeNewswire) - "Angion Biomedica Corp...announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070...at 10:00am EDT on Monday, September 20th. The event will feature presentations by...Gregory P. Downey, M.D., National Jewish Health, who will discuss the current treatment landscape and unmet medical needs of patients with lung fibrosis."

Review • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021 (GlobeNewswire) - P1, N=97; NCT04196179; Sponsor: Angion Biomedica Corp.; "Key findings from the ANG-3070 Phase 1 healthy volunteer study included: ANG-3070 achieved drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases....Pharmacokinetic data supportive of potential once-daily oral dosing for ANG-3070....The Company also announced it will host a Virtual Fibrosis R&D Day on September 20, 2021, at 10am US Eastern Daylight Time via a live online webcast. During the event, the Company will cover the potential of ANG-3070 for the treatment of kidney and lung fibrosis and provide additional data from preclinical studies of ANG-3070."

Clinical • P1 data • PK/PD data • Preclinical • Idiopathic Pulmonary Fibrosis

ANG-3070 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=97; Completed; Sponsor: Angion Biomedica Corp; Recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Mar 2021

Clinical • Trial completion • Trial completion date

A Phase 2, Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Angion Biomedica Corp

Clinical • New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease

ANG-3070 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Angion Biomedica Corp; Trial primary completion date: Aug 2020 ➔ Dec 2020

Clinical • Trial primary completion date

ANG-3070 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Angion Biomedica Corp; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

ANG-3070 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=80; Not yet recruiting; Sponsor: Angion Biomedica Corp

Clinical • New P1 trial